INCB054329, also known as pemigatinib, is a selective inhibitor of Fibroblast Growth Factor Receptor (FGFR) kinases, primarily used in oncology for treating cancers associated with FGFR mutations or fusions. It is effective against various malignancies, such as urothelial carcinoma (bladder cancer), cholangiocarcinoma, lung cancer, and breast cancer. By blocking abnormal FGFR signaling pathways, it inhibits cancer cell proliferation and survival. This compound shows particular promise for patients with relapsed or refractory cancers resistant to other therapies. Its efficacy and safety are being evaluated in ongoing clinical trials, both as monotherapy and in combination with other anticancer agents, to target specific molecular pathways involved in tumor growth and progression.